Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Takeda Prices Oral Multiple Myeloma Follow-On Ninlaro On Par With Velcade

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approval of the next-generation proteasome inhibitor ixazomib will pave the way for an all-oral combination with Revlimid and dexamethasone and give Takeda an opportunity to extend its oncology franchise beyond Velcade, which could see generic competition in late 2017.

Advertisement

Related Content

Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register